Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. has announced a significant Research and Development Tax Incentive refund of AUD $2,624,860.47 from the Australian Tax Office, supporting the company’s international efforts in infectious disease programs. The rebate, which complements a previous Australian portion received in late 2023, enhances Recce’s cash flow for its ongoing research into synthetic anti-infectives. The Australian Government’s tax incentive underlines national support for the company’s innovative work in developing treatments against antibiotic-resistant superbugs and viral pathogens.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
